Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOX
Background and Objectives Oxaliplatin can cause hepatic sinusoidal obstruction syndrome (SOS). SOS can cause chemotherapy‐related adverse effects or morbidity after liver resection. Conventionally, SOS is diagnosed using liver biopsy. Recently, it was reported that increased splenic volume (SV) can...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2017-12, Vol.116 (7), p.947-953 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 953 |
|---|---|
| container_issue | 7 |
| container_start_page | 947 |
| container_title | Journal of surgical oncology |
| container_volume | 116 |
| creator | Iwai, Takuma Yamada, Takeshi Koizumi, Michihiro Shinji, Seiichi Yokoyama, Yasuyuki Takahashi, Goro Takeda, Kohki Hara, Keisuke Ohta, Keiichiro Uchida, Eiji |
| description | Background and Objectives
Oxaliplatin can cause hepatic sinusoidal obstruction syndrome (SOS). SOS can cause chemotherapy‐related adverse effects or morbidity after liver resection. Conventionally, SOS is diagnosed using liver biopsy. Recently, it was reported that increased splenic volume (SV) can be used to detect SOS. In this study, we evaluated the changes in SV during adjuvant chemotherapy.
Methods
We enrolled 103 consecutive patients with stage III and high‐risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery. SV was measured three times; pre‐operatively, after chemotherapy, and 1 year after chemotherapy.
Results
SV was higher after mFOLFOX6 (median 135.89 mL) than pre‐operatively (105.75 mL) (P |
| doi_str_mv | 10.1002/jso.24756 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1936263515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1936263515</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4196-29de0a882ff0388c5f773086c13473c55ee150df1580a3b6b0a441495c5d54543</originalsourceid><addsrcrecordid>eNp10M9OGzEQBnALgSBQDrwAWokLPQTG6z9rixOKCG0VaQ-0UqUeVo53Fhw5u8HeTZsbj9Bn5EnqNpQDEieP5J8-zXyEnFC4oAD55SJ2FzkvhNwhIwpajjVotUtG6S8f80LDATmMcQEAWku-Tw5ypQrJBR-RH-Uv493Km961z0-_XVsPFuvMtTagiZiGLK48ts5m684PS7zKXAi4xhDd3GNmH0x7j5lpegyZqRfD2rR9Ni1n0_L7B7LXGB_x-OU9It-mN18nn8az8vbz5Ho2tpymZXNdIxil8qYBppQVTVEwUNJSxgtmhUCkAuqGCgWGzeUcDOeUa2FFLdIR7Iicb3NXoXscMPbV0kWL3psWuyFWVDOZSyaoSPTsDV10Q2jTdkkVoJRUmiX1cats6GIM2FSr4JYmbCoK1d_Gq9R49a_xZE9fEof5EutX-b_iBC634KfzuHk_qfpyV24j_wCOAoov</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1970886893</pqid></control><display><type>article</type><title>Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOX</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Iwai, Takuma ; Yamada, Takeshi ; Koizumi, Michihiro ; Shinji, Seiichi ; Yokoyama, Yasuyuki ; Takahashi, Goro ; Takeda, Kohki ; Hara, Keisuke ; Ohta, Keiichiro ; Uchida, Eiji</creator><creatorcontrib>Iwai, Takuma ; Yamada, Takeshi ; Koizumi, Michihiro ; Shinji, Seiichi ; Yokoyama, Yasuyuki ; Takahashi, Goro ; Takeda, Kohki ; Hara, Keisuke ; Ohta, Keiichiro ; Uchida, Eiji</creatorcontrib><description>Background and Objectives
Oxaliplatin can cause hepatic sinusoidal obstruction syndrome (SOS). SOS can cause chemotherapy‐related adverse effects or morbidity after liver resection. Conventionally, SOS is diagnosed using liver biopsy. Recently, it was reported that increased splenic volume (SV) can be used to detect SOS. In this study, we evaluated the changes in SV during adjuvant chemotherapy.
Methods
We enrolled 103 consecutive patients with stage III and high‐risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery. SV was measured three times; pre‐operatively, after chemotherapy, and 1 year after chemotherapy.
Results
SV was higher after mFOLFOX6 (median 135.89 mL) than pre‐operatively (105.75 mL) (P < 0.001); SV at 1‐year after finishing mFOLFOX6 (114.16 mL) returned to the same level as before surgery (P = 0.0015). SV increased in 28 patients (75.7%) treated with mFOLFOX6 (95%CI, 61.8‐89.5), but had not recovered in 12 of these cases (42.9%) 1 year after finishing treatment (95%CI, 17.3‐47.5). In contrast, oral fluorouracil and leucovorin did not change SV.
Conclusions
SV increased after adjuvant mFOLFOX6, and had not recovered in almost half of cases 1‐year after finishing chemotherapy. This increase may indicate continuous SOS, which can adversely affect treatment after recurrence.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.24756</identifier><identifier>PMID: 28876454</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>adjuvant chemotherapy ; Cancer surgery ; Chemotherapy ; Colorectal cancer ; mFOLFOX6 ; splenic volume</subject><ispartof>Journal of surgical oncology, 2017-12, Vol.116 (7), p.947-953</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4196-29de0a882ff0388c5f773086c13473c55ee150df1580a3b6b0a441495c5d54543</citedby><cites>FETCH-LOGICAL-c4196-29de0a882ff0388c5f773086c13473c55ee150df1580a3b6b0a441495c5d54543</cites><orcidid>0000-0002-4706-1228</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.24756$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.24756$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28876454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iwai, Takuma</creatorcontrib><creatorcontrib>Yamada, Takeshi</creatorcontrib><creatorcontrib>Koizumi, Michihiro</creatorcontrib><creatorcontrib>Shinji, Seiichi</creatorcontrib><creatorcontrib>Yokoyama, Yasuyuki</creatorcontrib><creatorcontrib>Takahashi, Goro</creatorcontrib><creatorcontrib>Takeda, Kohki</creatorcontrib><creatorcontrib>Hara, Keisuke</creatorcontrib><creatorcontrib>Ohta, Keiichiro</creatorcontrib><creatorcontrib>Uchida, Eiji</creatorcontrib><title>Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOX</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Background and Objectives
Oxaliplatin can cause hepatic sinusoidal obstruction syndrome (SOS). SOS can cause chemotherapy‐related adverse effects or morbidity after liver resection. Conventionally, SOS is diagnosed using liver biopsy. Recently, it was reported that increased splenic volume (SV) can be used to detect SOS. In this study, we evaluated the changes in SV during adjuvant chemotherapy.
Methods
We enrolled 103 consecutive patients with stage III and high‐risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery. SV was measured three times; pre‐operatively, after chemotherapy, and 1 year after chemotherapy.
Results
SV was higher after mFOLFOX6 (median 135.89 mL) than pre‐operatively (105.75 mL) (P < 0.001); SV at 1‐year after finishing mFOLFOX6 (114.16 mL) returned to the same level as before surgery (P = 0.0015). SV increased in 28 patients (75.7%) treated with mFOLFOX6 (95%CI, 61.8‐89.5), but had not recovered in 12 of these cases (42.9%) 1 year after finishing treatment (95%CI, 17.3‐47.5). In contrast, oral fluorouracil and leucovorin did not change SV.
Conclusions
SV increased after adjuvant mFOLFOX6, and had not recovered in almost half of cases 1‐year after finishing chemotherapy. This increase may indicate continuous SOS, which can adversely affect treatment after recurrence.</description><subject>adjuvant chemotherapy</subject><subject>Cancer surgery</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>mFOLFOX6</subject><subject>splenic volume</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp10M9OGzEQBnALgSBQDrwAWokLPQTG6z9rixOKCG0VaQ-0UqUeVo53Fhw5u8HeTZsbj9Bn5EnqNpQDEieP5J8-zXyEnFC4oAD55SJ2FzkvhNwhIwpajjVotUtG6S8f80LDATmMcQEAWku-Tw5ypQrJBR-RH-Uv493Km961z0-_XVsPFuvMtTagiZiGLK48ts5m684PS7zKXAi4xhDd3GNmH0x7j5lpegyZqRfD2rR9Ni1n0_L7B7LXGB_x-OU9It-mN18nn8az8vbz5Ho2tpymZXNdIxil8qYBppQVTVEwUNJSxgtmhUCkAuqGCgWGzeUcDOeUa2FFLdIR7Iicb3NXoXscMPbV0kWL3psWuyFWVDOZSyaoSPTsDV10Q2jTdkkVoJRUmiX1cats6GIM2FSr4JYmbCoK1d_Gq9R49a_xZE9fEof5EutX-b_iBC634KfzuHk_qfpyV24j_wCOAoov</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Iwai, Takuma</creator><creator>Yamada, Takeshi</creator><creator>Koizumi, Michihiro</creator><creator>Shinji, Seiichi</creator><creator>Yokoyama, Yasuyuki</creator><creator>Takahashi, Goro</creator><creator>Takeda, Kohki</creator><creator>Hara, Keisuke</creator><creator>Ohta, Keiichiro</creator><creator>Uchida, Eiji</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4706-1228</orcidid></search><sort><creationdate>20171201</creationdate><title>Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOX</title><author>Iwai, Takuma ; Yamada, Takeshi ; Koizumi, Michihiro ; Shinji, Seiichi ; Yokoyama, Yasuyuki ; Takahashi, Goro ; Takeda, Kohki ; Hara, Keisuke ; Ohta, Keiichiro ; Uchida, Eiji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4196-29de0a882ff0388c5f773086c13473c55ee150df1580a3b6b0a441495c5d54543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>adjuvant chemotherapy</topic><topic>Cancer surgery</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>mFOLFOX6</topic><topic>splenic volume</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iwai, Takuma</creatorcontrib><creatorcontrib>Yamada, Takeshi</creatorcontrib><creatorcontrib>Koizumi, Michihiro</creatorcontrib><creatorcontrib>Shinji, Seiichi</creatorcontrib><creatorcontrib>Yokoyama, Yasuyuki</creatorcontrib><creatorcontrib>Takahashi, Goro</creatorcontrib><creatorcontrib>Takeda, Kohki</creatorcontrib><creatorcontrib>Hara, Keisuke</creatorcontrib><creatorcontrib>Ohta, Keiichiro</creatorcontrib><creatorcontrib>Uchida, Eiji</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwai, Takuma</au><au>Yamada, Takeshi</au><au>Koizumi, Michihiro</au><au>Shinji, Seiichi</au><au>Yokoyama, Yasuyuki</au><au>Takahashi, Goro</au><au>Takeda, Kohki</au><au>Hara, Keisuke</au><au>Ohta, Keiichiro</au><au>Uchida, Eiji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOX</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>116</volume><issue>7</issue><spage>947</spage><epage>953</epage><pages>947-953</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background and Objectives
Oxaliplatin can cause hepatic sinusoidal obstruction syndrome (SOS). SOS can cause chemotherapy‐related adverse effects or morbidity after liver resection. Conventionally, SOS is diagnosed using liver biopsy. Recently, it was reported that increased splenic volume (SV) can be used to detect SOS. In this study, we evaluated the changes in SV during adjuvant chemotherapy.
Methods
We enrolled 103 consecutive patients with stage III and high‐risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery. SV was measured three times; pre‐operatively, after chemotherapy, and 1 year after chemotherapy.
Results
SV was higher after mFOLFOX6 (median 135.89 mL) than pre‐operatively (105.75 mL) (P < 0.001); SV at 1‐year after finishing mFOLFOX6 (114.16 mL) returned to the same level as before surgery (P = 0.0015). SV increased in 28 patients (75.7%) treated with mFOLFOX6 (95%CI, 61.8‐89.5), but had not recovered in 12 of these cases (42.9%) 1 year after finishing treatment (95%CI, 17.3‐47.5). In contrast, oral fluorouracil and leucovorin did not change SV.
Conclusions
SV increased after adjuvant mFOLFOX6, and had not recovered in almost half of cases 1‐year after finishing chemotherapy. This increase may indicate continuous SOS, which can adversely affect treatment after recurrence.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28876454</pmid><doi>10.1002/jso.24756</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4706-1228</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2017-12, Vol.116 (7), p.947-953 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1936263515 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | adjuvant chemotherapy Cancer surgery Chemotherapy Colorectal cancer mFOLFOX6 splenic volume |
| title | Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOX |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T08%3A10%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxaliplatin%E2%80%90induced%20increase%20in%20splenic%20volume;%20irreversible%20change%20after%20adjuvant%20FOLFOX&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Iwai,%20Takuma&rft.date=2017-12-01&rft.volume=116&rft.issue=7&rft.spage=947&rft.epage=953&rft.pages=947-953&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.24756&rft_dat=%3Cproquest_cross%3E1936263515%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1970886893&rft_id=info:pmid/28876454&rfr_iscdi=true |